

3.2 Conclusion

The synthesis and characterization of a new series of 2-methyl-1-[t-amino-2-butynl]-2,3-dihydro-1H-indole, (AZ2-AZ7) were accomplished. Docking of the new aminoacetylenic 2-methylindoline compounds showed promising approach in the treatment of cancer and other angiogenic related disease like diabetic retinopathy and rheumatoid arthritis through inhibiting activity on EGF receptor and COX receptors. We are in the right track to find out more potent compounds through further structural modifications.